Yitian Zhou

Yitian Zhou

Postdoctoral Researcher
Visiting address: Solnavägen 9, Biomedicum, 17165 Solna
Postal address: C3 Fysiologi och farmakologi, C3 FyFa Individanpassad medicin och läkemedelsutveckling, 171 77 Stockholm
Part of:

About me

  • Affiliation: LabMed https://ki.se/en/labmed/department-of-laboratory-medicine CBB https://ki.se/en/research/centre-for-bioinformatics-and-biostatistics-cbb *Publications* Siamoglou S, Koromina M, Hishinuma E, Yamazaki S, Tsermpini E, Kordou Z, Fukunaga K, Chantratita W, *Zhou Y*, Lauschke VM, Mushiroda T, Hiratsuka M, Patrinos GP. Identification and functional validation of novel pharmacogenomic variants using a next-generation sequencing-based approach for clinical pharmacogenomics./Pharmacological Research/. 2022 Feb
  • 176:106087. Yang M, Johnsson P, Bräutigam L, Yang XR, Thrane K, Gao J, Tobin NP, *Zhou Y, *et al. Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma. /Genetics in Medicine/. 2022 Jan
  • 24(1):157-169. Genvigir FD Vecchia, Hernandez CD, Hirata TDC, *Zhou Y*, Lauschke VM, Hirata MH, Hirata RDC. Pharmacogenomics of Antihypertensive Drugs in Brazil: recent progress and clinical implications. /Endocrine, Metabolic & Immune Disorders Drug Targets/. 2021 Dec 22. *Zhou Y*, Lauschke VM. Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. /Human Genetics./ 2021 Oct 15. *Zhou Y*, Arribas G. H., Turku A., Lauschke VM et al. Rare genetic variability in human drugtarget genes modulates drug response and can guide precision medicine. /Science Advances/. 2021 Sep 3
  • 7(36) Dagli-Hernandez C., *Zhou Y*, Lauschke VM, et al. Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts. /Pharmacological Reports/. 2021. Hirata T. D. C., Dagli-Hernandez, C., Genvigir, F. D. V., Lauschke VM, *Zhou Y*, et al. Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients. /Molecular Diagnosis & Therapy/. 2021. *Zhou Y*, Lauschke VM. Computational tools to assess the functional consequences of rare and noncoding pharmacogenetic variability. /Clinical Pharmacology & Therapeutics/. 2021
  • 17. Russell LE, *Zhou Y*, Almousa AA, Sodhi JK, Nwabufo CK, Lauschke VM. Pharmacogenomics in the era of next generation sequencing - from byte to bedside. /Drug Metabolism Reviews/. 2021
  • 17:1-26. Pernaute-Lau L, Adegnika AA, *Zhou Y*, Zinsou JF, et al. Pharmacogene sequencing of a Gabonese population with severe Plasmodium falciparum malaria reveals multiple novel variants with putative relevance for antimalarial treatment. /Antimicrobial Agents and Chemotherapy/. 2021
  • 19:AAC.00275-21. Wang T, *Zhou Y*, Cao G. Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes. /European Journal of Clinical Pharmacology/. 2021
  • 1-17 Xiao Q, *Zhou Y*, Lauschke VM. Impact of variants in ATP-binding cassette transporters on breast cancer treatment. /Pharmacogenomics/. 2021
  • 21 (18), 1299-1310 *Zhou Y*, Hernandez C D, Lauschke VM. Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier. /British Journal of Cancer/. 2020 *Zhou Y*, Krebs K, Milani L, Lauschke VM. Global frequencies of clinically important HLA alleles and their implications for the cost‐effectiveness of preemptive pharmacogenetic testing. /Clinical Pharmacology & Therapeutics/. 2020 Xiao Q, *Zhou Y*, Winter S, Büttner F, Schaeffeler E, Schwab M, et al. Germline variant burden in multidrug resistance transporters is a therapy‐specific predictor of survival in breast cancer patients. /International Journal of Cancer/. 2020
  • 146 (9), 2475-2487 Xiao Q, *Zhou Y*, Lauschke VM. Ethnogeographic and inter-individual variability of human ABC transporters. /Human Genetics/. 2020
  • 1–24. Russell LE, *Zhou Y*, Lauschke VM, Kim RB. In Vitro Functional Characterization and in Silico Prediction of Rare Genetic Variation in the Bile Acid and Drug Transporter, Na+-Taurocholate Cotransporting Polypeptide (NTCP, SLC10A1). /Molecular Pharmaceutics/. 2020 Feb 26
  • 17(4):1170–81. *Zhou Y*, Lauschke VM. Pharmacogenomic network analysis of the gene-drug interaction landscape underlying drug disposition. /Computational and Structural Biotechnology Journal/. 2020
  • 18:52–8. Lauschke VM, Nordling Å, *Zhou Y*, Fontalva S, Barragan I, Ingelman-Sundberg M. CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma. /Pharmacogenomics/. 2019
  • 20(15):1085–92. *Zhou Y*, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke VM. An optimized prediction framework to assess the functional impact of pharmacogenetic variants. /The pharmacogenomics journal/. 2018 Sep 12
  • 28(Suppl 3):1. Lauschke VM, *Zhou Y*, Ingelman-Sundberg M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. /Pharmacology & therapeutics/. 2019 May 1
  • 197:122–52. *Zhou Y*, Shen J, Lauschke VM. Comprehensive evaluation of current organotypic and microphysiological liver models for prediction of drug-induced liver injury. /Frontiers in pharmacology./ 2019
  • 10:1093. *Zhou Y*, Fujikura K, Mkrtchian S, Lauschke VM. Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data. /Frontiers in pharmacology/. 2018 Dec 4
  • 9:248. Ingelman-Sundberg M, Mkrtchian S, *Zhou Y*, Lauschke VM. Integrating rare genetic variants into pharmacogenetic drug response predictions. /Human Genomics/. 2018 Dec 1
  • 12(1):26. *Zhou Y*, Mägi R, Milani L, Lauschke VM. Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk. /Journal of lipid research/. 2018 Oct
  • 59(10):1987–2000. *Zhou Y*, Lauschke VM. Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews. /Journal of Medical Genetics/. 2018 Sep 1
  • 55(9):617–27. Vorrink SU, *Zhou Y*, Ingelman-Sundberg M, Lauschke VM. Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions. /Toxicological Sciences/. 2018
  • 163(2):655–65. *Zhou Y*, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta‐analysis of population‐scale sequencing projects. /Clinical Pharmacology & Therapeutics/. 2017
  • 102(4):688–700. *Zhou Y*, Zhou P, Xin Y, Wang J, Zhu Z, Hu J, et al. Trend of telomerase activity change during human iPSC self-renewal and differentiation revealed by a quartz crystal microbalance based assay. /Scientific reports/. 2014
  • 4:6978. Lv B, *Zhou Y*, Cha W, Wu Y, Hu J, Li L, et al. Molecular composition, grafting density and film area affect the swelling-induced Au–S bond breakage. /ACS applied materials & interfaces/. 2014
  • 6(11):8313–9. 2017-2021, Karolinska Institutet, PhD in Pharmacogenetics 2015-2017, Karolinska Institutet, Master of Medical Science in Toxicology 2008-2012, China Pharmaceutical University, Bachelor of Science in Pharmacy

Articles

All other publications

Employments

  • Postdoctoral Researcher, Department of Physiology and Pharmacology, Karolinska Institutet, 2023-2025

Degrees and Education

  • Degree Of Doctor Of Philosophy, Department of Physiology and Pharmacology, Karolinska Institutet, 2021
  • Degree Of Master Of Medical Science 120 Credits, Karolinska Institutet, 2017

News from KI

Events from KI